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Extended operation for recurrent thymic carcinoma presenting with
intracaval growth and intracardiac extension
Tiziano De Giacomo, MD, Giuseppe Mazzesi, MD, Federico Venuta, MD, and G. F. Coloni, MD, Rome, Italy
Thymic carcinoma is a relatively uncommon tumor thatrepresents less than 1% of thymic malignancies. Theprognosis is often poor, with a 5-year survival for allpatients of between 31% and 50%.1 At present, a mul-
timodality approach including aggressive surgical resection, platinum-
based combination chemotherapy, and radiotherapy seems the pre-
ferred therapeutic strategy. Overall recurrence rate is very high and
vascular invasion is particularly associated with poor prognosis.2,3
Only aggressive and complete resection yields long-term survival.
We report the management of recurrent thymic carcinoma with
extension into the right atrium, resulting from the progression of
intracaval growth, 4 years after induction chemotherapy and suc-
cessful total resection followed by chemoradiation treatment.
Clinical Summary
A 46-year-old man with sudden engorgement of neck veins, swell-
ing of the face, and mild ocular myasthenia was admitted to our
institution. Recurrence of thymic carcinoma was suspected inas-
much as the patient had undergone radical resection, with negative
resection margins, of thymic carcinoma 4 years earlier, after in-
duction chemotherapy. The patient received postoperative adju-
vant therapy, including 6 cycles of platinum-based chemotherapy
followed by 40 Gy of mediastinal irradiation. Contrast-enhanced
computed tomographic scanning of the chest revealed an inhomo-
geneous mass almost completely obstructing the superior vena
cava (SVC) and extending into the right atrium without evidence
of tumor recurrence around the vessel, into the mediastinum, or in
other sites. A magnetic resonance image confirmed the presence of
a continuous pathologic tissue growing into the SVC and into the
right atrium (Figure 1). A transthoracic echocardiogram showed a
mass that almost completely filled the right atrium but was unable
to show its relation to the great veins. A transesophageal echocar-
diogram confirmed the mass in the right atrium, which was con-
nected to the mass into the SVC; no other significant abnormalities
were found in the remaining cardiac chambers, valves, and great
vessels.
The patient was operated on through a median resternotomy.
Exploration of the mediastinum did not demonstrate extravascular
recurrence of the tumor or malignant lymphoadenopathies. Extra-
corporeal circulation was instituted by cannulating separately in-
ferior vena cava and SVC immediately after the confluence of the
innominate vessel over the edge of the intracaval mass. Opening
the right atrium, without cardiac arrest, revealed a large tumor
strictly adherent to the cava–atrial junction, completely obstructing
the SVC. The mass was resected en bloc with the infiltrated portion
of the atrial wall and the SVC.
The right atrium was reconstructed with a patch of bovine
pericardium, and the same material was shaped into a tube, with a
linear stapler, and used for SVC substitution (Figure 2). The
postoperative course was uneventful. Anticoagulation therapy was
started to prevent thrombosis of the extensive pericardial recon-
struction of the SVC and right atrium.
Definitive pathologic examination showed that resection mar-
gins were negative and the tumor was a well-differentiated thymic
carcinoma (B3 of the World Health Organization classification). A
postoperative echocardiogram demonstrated that the right atrium
was completely free of tumor, and a contrast-enhanced computed
tomographic scan of the chest confirmed the normal flow in the
SVC district.
Subsequent treatment included 4 cycles of platinum-based che-
motherapy. One year after the operation the patient is alive and
well without evidence of disease.
Discussion
The optimum treatment protocol for thymic carcinoma remains
undetermined, although at present a multimodality approach in-
volving aggressive surgical resection, platinum-based combination
chemotherapy, and radiotherapy represents the preferred therapeu-
tic strategy. Overall, prognosis is poor and reported recurrence rate
very high (65% at 5 years and 75% at 10 years).2 Five-year
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Figure 1. Magnetic resonance image of the chest showing the
tumor growing into the superior vena cava and extending into the
right atrium.
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survivals for total resection, subtotal resection, and inoperable
groups are 67%, 30%, and 24%, respectively,4 suggesting that only
patients undergoing complete resection have a chance of long-term
survival. Local regional invasion of nearby organs by thymic
carcinoma is very common, but vascular invasion (innominate
vessel, SVC, pulmonary vessels, or aorta) seems to be the only
statistically significant predictor of poor survival according to
univariate analysis.2 This observation has been confirmed more
recently by Tseng and coworkers.3 Also, histologic type seems to
have an impact on prognosis: well-differentiated thymic carci-
noma, defined as a low-grade malignancy, was reported as the
most reliable predictor of prognosis.4
Resection of thymic carcinoma presenting with intravascular
growth in the SVC and right atrium has been rarely reported in the
literature5 inasmuch as the most common cause of SVC syndrome
is extrinsic compression rather than intracaval or intracardiac
growth. However, invasion of the SVC and right atrium do not
preclude surgery in selected cases because the only chance for
long-term survival is complete resection. Surgery should not be
indicated if extensive local invasion or distant metastases preclude
radical resection. Even for recurrent thymic carcinoma, surgery
remains the therapy of choice inasmuch as most of the cases recur
even after complete resection.
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Figure 2. Intraoperative photograph at the end of the operation:
the complete reconstruction of the superior vena cava with the
pericardial tube and the patch on the right atrium are clearly
visible.
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